In this retrospective cohort study, the researchers examined the association of hospice care with Medicare plan switching among individuals who died with advanced cancer.
The EPA estimated that the proposed rule would result in total capital investment cost savings of roughly $280 million across commercial sterilization facilities and an annual compliance cost savings ...
Researchers compared clinicopathologic features, MammaPrint and BluePrint molecular subtype, and outcomes by race among patients with HR+, HER2− early-stage breast cancer.
In undertaking this survey, researchers aimed to assess the limitations of ctDNA testing in the clinic, as well as areas in which it is considered clinically meaningful.
Now, without that federal financial help, some in this age group say they’re wrestling with whether to delay care until they ...
Investigators expanded on previous results from the DEAR study, comparing darolutamide versus enzalutamide and apalutamide ...
(HealthDay News) — For patients with breast cancer, administration of pegfilgrastim 72 hours postchemotherapy reduces pegfilgrastim-induced bone pain (PIBP) compared with administration at 24 and 48 ...
Incidence and diagnosis of neuroendocrine tumors (NETs) have risen significantly over the last several decades. According to research published in JAMA Network Open in 2025, the incidence of NETs ...
SCLC, researchers aimed to determine the consistency of benefit of adding PD-1/PD-L1 inhibitors to platinum-etoposide.
In this study, researchers aimed to identify factors associated with COVID-19 severity in gynecologic cancer patients.
FDA approval of Lifyorli plus nab-paclitaxel offers a new option for platinum-resistant epithelial ovarian cancer after 1 to 3 prior systemic regimens.
The oral molecular glue degrader aims to overcome resistance to standard ALK tyrosine kinase inhibitor therapies.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results